AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Courier Capital LLC

Courier Capital LLC lessened its stake in AstraZeneca PLC (NASDAQ:AZN) by 4.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,317 shares of the company’s stock after selling 400 shares during the quarter. Courier Capital LLC’s holdings in AstraZeneca were worth $726,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. TD Asset Management Inc increased its stake in shares of AstraZeneca by 8.6% in the 1st quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock valued at $104,160,000 after purchasing an additional 121,876 shares in the last quarter. Northcape Wealth Management LLC purchased a new position in shares of AstraZeneca in the 2nd quarter valued at about $269,000. Wealthcare Advisory Partners LLC increased its stake in AstraZeneca by 9.7% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company’s stock worth $416,000 after buying an additional 543 shares in the last quarter. Cetera Advisors LLC increased its stake in AstraZeneca by 124.5% during the 1st quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock worth $6,657,000 after buying an additional 54,488 shares in the last quarter. Finally, Diversify Advisory Services LLC purchased a new stake in AstraZeneca during the 1st quarter worth approximately $836,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on AZN. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Price Performance

AZN stock opened at $76.95 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The business has a 50 day simple moving average of $80.91 and a 200-day simple moving average of $78.42. The firm has a market capitalization of $238.59 billion, a PE ratio of 37.17, a price-to-earnings-growth ratio of 1.43 and a beta of 0.46. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. The business had revenue of $12.45 billion during the quarter, compared to analyst estimates of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the business earned $1.08 earnings per share. Equities research analysts anticipate that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.